HEADER HYDROLASE/HYDROLASE INHIBITOR 16-OCT-19 5QTU TITLE FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(3R,7S)-7-{[1-(3- TITLE 2 CHLORO-2-FLUOROPHENYL)-5-METHYL-1H-IMIDAZOLE-4-CARBONYL]AMINO}-3- TITLE 3 METHYL-2-OXO-2,3,4,5,6,7-HEXAHYDRO-1H-12,8-(METHENO)-1,9- TITLE 4 BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE COMPND MOL_ID: 1; COMPND 2 MOLECULE: COAGULATION FACTOR XI; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: COAGULATION FACTOR XI, HEAVY CHAIN; COMPND 5 SYNONYM: FXI,PLASMA THROMBOPLASTIN ANTECEDENT,PTA; COMPND 6 EC: 3.4.21.27; COMPND 7 ENGINEERED: YES; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: COAGULATION FACTOR XI; COMPND 10 CHAIN: H; COMPND 11 SYNONYM: FXI,PLASMA THROMBOPLASTIN ANTECEDENT,PTA; COMPND 12 EC: 3.4.21.27; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: F11; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET14B; SOURCE 10 MOL_ID: 2; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606; SOURCE 14 GENE: F11; SOURCE 15 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 16 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 17 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 18 EXPRESSION_SYSTEM_PLASMID: PET14B KEYWDS HYDROLASE, SERINE PROTEASE, BLOOD COAGULATION FACTOR, PROTEIN KEYWDS 2 INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR S.SHERIFF REVDAT 3 12-MAY-21 5QTU 1 JRNL REVDAT 2 29-JAN-20 5QTU 1 JRNL REVDAT 1 25-DEC-19 5QTU 0 JRNL AUTH J.R.CORTE,D.J.P.PINTO,T.FANG,H.OSUNA,W.YANG,Y.WANG,A.LAI, JRNL AUTH 2 C.CLARK,J.H.SUN,R.A.RAMPULLA,A.MATHUR,M.KASPADY, JRNL AUTH 3 P.R.NEITHNADKA,Y.X.LI,K.A.ROSSI,J.E.MYERS,S.SHERIFF,Z.LOU, JRNL AUTH 4 T.W.HARPER,C.S.HUANG,J.J.ZHENG,J.M.BOZARTH,Y.WU,P.C.WONG, JRNL AUTH 5 E.CRAIN,D.A.SEIFFERT,J.M.LUETTGEN,P.LAM,R.R.WEXLER,W.R.EWING JRNL TITL POTENT, ORALLY BIOAVAILABLE AND EFFICACIOUS MACROCYCLIC JRNL TITL 2 INHIBITORS OF FACTOR XIA. DISCOVERY OF PYRIDINE-BASED JRNL TITL 3 MACROCYCLES POSSESSING PHENYLAZOLE CARBOXAMIDE P1 GROUPS. JRNL REF J.MED.CHEM. V. 63 784 2019 JRNL REFN ISSN 0022-2623 JRNL PMID 31833761 JRNL DOI 10.1021/ACS.JMEDCHEM.9B01768 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH M.L.QUAN,P.C.WONG,C.WANG,F.WOERNER,J.M.SMALLHEER, REMARK 1 AUTH 2 F.A.BARBERA,J.M.BOZARTH,R.L.BROWN,M.R.HARPEL,J.M.LUETTGEN, REMARK 1 AUTH 3 P.E.MORIN,T.PETERSON,V.RAMAMURTHY,A.R.RENDINA,K.A.ROSSI, REMARK 1 AUTH 4 C.A.WATSON,A.WEI,G.ZHANG,D.SEIFFERT,R.R.WEXLER REMARK 1 TITL TETRAHYDROQUINOLINE DERIVATIVES AS POTENT AND SELECTIVE REMARK 1 TITL 2 FACTOR XIA INHIBITORS. REMARK 1 REF J. MED. CHEM. V. 57 955 2014 REMARK 1 REFN ISSN 1520-4804 REMARK 1 PMID 24405333 REMARK 1 DOI 10.1021/JM401670X REMARK 1 REFERENCE 2 REMARK 1 AUTH J.J.HANGELAND,T.J.FRIENDS,K.A.ROSSI,J.M.SMALLHEER,C.WANG, REMARK 1 AUTH 2 Z.SUN,J.R.CORTE,T.FANG,P.C.WONG,A.R.RENDINA,F.A.BARBERA, REMARK 1 AUTH 3 J.M.BOZARTH,J.M.LUETTGEN,C.A.WATSON,G.ZHANG,A.WEI, REMARK 1 AUTH 4 V.RAMAMURTHY,P.E.MORIN,G.S.BISACCHI,S.SUBRAMANIAM, REMARK 1 AUTH 5 P.ARUNACHALAM,A.MATHUR,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL PHENYLIMIDAZOLES AS POTENT AND SELECTIVE INHIBITORS OF REMARK 1 TITL 2 COAGULATION FACTOR XIA WITH IN VIVO ANTITHROMBOTIC ACTIVITY. REMARK 1 REF J. MED. CHEM. V. 57 9915 2014 REMARK 1 REFN ISSN 1520-4804 REMARK 1 PMID 25405503 REMARK 1 DOI 10.1021/JM5010607 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.R.CORTE,T.FANG,J.J.HANGELAND,T.J.FRIENDS,A.R.RENDINA, REMARK 1 AUTH 2 J.M.LUETTGEN,J.M.BOZARTH,F.A.BARBERA,K.A.ROSSI,A.WEI, REMARK 1 AUTH 3 V.RAMAMURTHY,P.E.MORIN,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL PYRIDINE AND PYRIDINONE-BASED FACTOR XIA INHIBITORS. REMARK 1 REF BIOORG. MED. CHEM. LETT. V. 25 925 2015 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 25592713 REMARK 1 DOI 10.1016/J.BMCL.2014.12.050 REMARK 1 REFERENCE 4 REMARK 1 AUTH D.J.PINTO,J.M.SMALLHEER,J.R.CORTE,E.J.AUSTIN,C.WANG,T.FANG, REMARK 1 AUTH 2 L.M.SMITH 2ND.,K.A.ROSSI,A.R.RENDINA,J.M.BOZARTH,G.ZHANG, REMARK 1 AUTH 3 A.WEI,V.RAMAMURTHY,S.SHERIFF,J.E.MYERS JR.,P.E.MORIN, REMARK 1 AUTH 4 J.M.LUETTGEN,D.A.SEIFFERT,M.L.QUAN,R.R.WEXLER REMARK 1 TITL STRUCTURE-BASED DESIGN OF INHIBITORS OF COAGULATION FACTOR REMARK 1 TITL 2 XIA WITH NOVEL P1 MOIETIES. REMARK 1 REF BIOORG. MED. CHEM. LETT. V. 25 1635 2015 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 25728130 REMARK 1 DOI 10.1016/J.BMCL.2015.01.028 REMARK 1 REFERENCE 5 REMARK 1 AUTH Z.HU,P.C.WONG,P.J.GILLIGAN,W.HAN,K.B.PABBISETTY,J.M.BOZARTH, REMARK 1 AUTH 2 E.J.CRAIN,T.HARPER,J.M.LUETTGEN,J.E.MYERS JR.,V.RAMAMURTHY, REMARK 1 AUTH 3 K.A.ROSSI,S.SHERIFF,C.A.WATSON,A.WEI,J.J.ZHENG,D.A.SEIFFERT, REMARK 1 AUTH 4 R.R.WEXLER,M.L.QUAN REMARK 1 TITL DISCOVERY OF A POTENT PARENTERALLY ADMINISTERED FACTOR XIA REMARK 1 TITL 2 INHIBITOR WITH HYDROXYQUINOLIN-2(1H)-ONE AS THE P2' MOIETY. REMARK 1 REF ACS MED CHEM LETT V. 6 590 2015 REMARK 1 REFN ISSN 1948-5875 REMARK 1 PMID 26005539 REMARK 1 DOI 10.1021/ACSMEDCHEMLETT.5B00066 REMARK 1 REFERENCE 6 REMARK 1 AUTH L.M.SMITH 2ND.,M.J.ORWAT,Z.HU,W.HAN,C.WANG,K.A.ROSSI, REMARK 1 AUTH 2 P.J.GILLIGAN,K.B.PABBISETTY,H.OSUNA,J.R.CORTE,A.R.RENDINA, REMARK 1 AUTH 3 J.M.LUETTGEN,P.C.WONG,R.NARAYANAN,T.W.HARPER,J.M.BOZARTH, REMARK 1 AUTH 4 E.J.CRAIN,A.WEI,V.RAMAMURTHY,P.E.MORIN,B.XIN,J.ZHENG, REMARK 1 AUTH 5 D.A.SEIFFERT,M.L.QUAN,P.Y.S.LAM,R.R.WEXLER,D.J.P.PINTO REMARK 1 TITL NOVEL PHENYLALANINE DERIVED DIAMIDES AS FACTOR XIA REMARK 1 TITL 2 INHIBITORS. REMARK 1 REF BIOORG. MED. CHEM. LETT. V. 26 472 2016 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 26704266 REMARK 1 DOI 10.1016/J.BMCL.2015.11.089 REMARK 1 REFERENCE 7 REMARK 1 AUTH J.R.CORTE,T.FANG,D.J.PINTO,M.J.ORWAT,A.R.RENDINA, REMARK 1 AUTH 2 J.M.LUETTGEN,K.A.ROSSI,A.WEI,V.RAMAMURTHY,J.E.MYERS JR., REMARK 1 AUTH 3 S.SHERIFF,R.NARAYANAN,T.W.HARPER,J.J.ZHENG,Y.X.LI, REMARK 1 AUTH 4 D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL ORALLY BIOAVAILABLE PYRIDINE AND PYRIMIDINE-BASED FACTOR XIA REMARK 1 TITL 2 INHIBITORS: DISCOVERY OF THE METHYL N-PHENYL CARBAMATE P2 REMARK 1 TITL 3 PRIME GROUP. REMARK 1 REF BIOORG. MED. CHEM. V. 24 2257 2016 REMARK 1 REFN ESSN 1464-3391 REMARK 1 PMID 27073051 REMARK 1 DOI 10.1016/J.BMC.2016.03.062 REMARK 1 REFERENCE 8 REMARK 1 AUTH J.R.CORTE,T.FANG,H.OSUNA,D.J.PINTO,K.A.ROSSI,J.E.MYERS JR., REMARK 1 AUTH 2 S.SHERIFF,Z.LOU,J.J.ZHENG,T.W.HARPER,J.M.BOZARTH,Y.WU, REMARK 1 AUTH 3 J.M.LUETTGEN,D.A.SEIFFERT,C.P.DECICCO,R.R.WEXLER,M.L.QUAN REMARK 1 TITL STRUCTURE-BASED DESIGN OF MACROCYCLIC FACTOR XIA INHIBITORS: REMARK 1 TITL 2 DISCOVERY OF THE MACROCYCLIC AMIDE LINKER. REMARK 1 REF J. MED. CHEM. V. 60 1060 2017 REMARK 1 REFN ISSN 1520-4804 REMARK 1 PMID 28085275 REMARK 1 DOI 10.1021/ACS.JMEDCHEM.6B01460 REMARK 1 REFERENCE 9 REMARK 1 AUTH J.R.CORTE,W.YANG,T.FANG,Y.WANG,H.OSUNA,A.LAI,W.R.EWING, REMARK 1 AUTH 2 K.A.ROSSI,J.E.MYERS JR.,S.SHERIFF,Z.LOU,J.J.ZHENG, REMARK 1 AUTH 3 T.W.HARPER,J.M.BOZARTH,Y.WU,J.M.LUETTGEN,D.A.SEIFFERT, REMARK 1 AUTH 4 M.L.QUAN,R.R.WEXLER,P.Y.S.LAM REMARK 1 TITL MACROCYCLIC INHIBITORS OF FACTOR XIA: DISCOVERY OF REMARK 1 TITL 2 ALKYL-SUBSTITUTED MACROCYCLIC AMIDE LINKERS WITH IMPROVED REMARK 1 TITL 3 POTENCY. REMARK 1 REF BIOORG. MED. CHEM. LETT. V. 27 3833 2017 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 28687203 REMARK 1 DOI 10.1016/J.BMCL.2017.06.058 REMARK 1 REFERENCE 10 REMARK 1 AUTH C.WANG,J.R.CORTE,K.A.ROSSI,J.M.BOZARTH,Y.WU,S.SHERIFF, REMARK 1 AUTH 2 J.E.MYERS JR.,J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER,M.L.QUAN REMARK 1 TITL MACROCYCLIC FACTOR XIA INHIBITORS. REMARK 1 REF BIOORG. MED. CHEM. LETT. V. 27 4056 2017 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 28780160 REMARK 1 DOI 10.1016/J.BMCL.2017.07.048 REMARK 1 REFERENCE 11 REMARK 1 AUTH D.J.P.PINTO,M.J.ORWAT,L.M.SMITH 2ND.,M.L.QUAN,P.Y.S.LAM, REMARK 1 AUTH 2 K.A.ROSSI,A.APEDO,J.M.BOZARTH,Y.WU,J.J.ZHENG,B.XIN, REMARK 1 AUTH 3 N.TOUSSAINT,P.STETSKO,O.GUDMUNDSSON,B.MAXWELL,E.J.CRAIN, REMARK 1 AUTH 4 P.C.WONG,Z.LOU,T.W.HARPER,S.A.CHACKO,J.E.MYERS JR., REMARK 1 AUTH 5 S.SHERIFF,H.ZHANG,X.HOU,A.MATHUR,D.A.SEIFFERT,R.R.WEXLER, REMARK 1 AUTH 6 J.M.LUETTGEN,W.R.EWING REMARK 1 TITL DISCOVERY OF A PARENTERAL SMALL MOLECULE COAGULATION FACTOR REMARK 1 TITL 2 XIA INHIBITOR CLINICAL CANDIDATE (BMS-962212). REMARK 1 REF J. MED. CHEM. V. 60 9703 2017 REMARK 1 REFN ISSN 1520-4804 REMARK 1 PMID 29077405 REMARK 1 DOI 10.1021/ACS.JMEDCHEM.7B01171 REMARK 1 REFERENCE 12 REMARK 1 AUTH C.G.CLARK,K.A.ROSSI,J.R.CORTE,T.FANG,J.M.SMALLHEER, REMARK 1 AUTH 2 I.DE LUCCA,D.S.NIRSCHL,M.J.ORWAT,D.J.P.PINTO,Z.HU,Y.WANG, REMARK 1 AUTH 3 W.YANG,Y.JEON,W.R.EWING,J.E.MYERS JR.,S.SHERIFF,Z.LOU, REMARK 1 AUTH 4 J.M.BOZARTH,Y.WU,A.RENDINA,T.HARPER,J.ZHENG,B.XIN,Q.XIANG, REMARK 1 AUTH 5 J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER,P.Y.S.LAM REMARK 1 TITL STRUCTURE BASED DESIGN OF MACROCYCLIC FACTOR XIA INHIBITORS: REMARK 1 TITL 2 DISCOVERY OF CYCLIC P1 LINKER MOIETIES WITH IMPROVED ORAL REMARK 1 TITL 3 BIOAVAILABILITY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 29 26604 2019 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 31445854 REMARK 1 DOI 10.1016/J.BMCL.2019.08.008 REMARK 1 REFERENCE 13 REMARK 1 AUTH T.FANG,J.R.CORTE,P.J.GILLIGAN,Y.JEON,H.OSUNA,K.A.ROSSI, REMARK 1 AUTH 2 J.E.MYERS JR.,S.SHERIFF,Z.LOU,J.J.ZHENG,T.W.HARPER, REMARK 1 AUTH 3 J.M.BOZARTH,Y.WU,J.M.LUETTGEN,D.A.SEIFFERT,R.R.WEXLER, REMARK 1 AUTH 4 P.Y.S.LAM REMARK 1 TITL ORALLY BIOAVAILABLE AMINE-LINKED MACROCYCLIC INHIBITORS OF REMARK 1 TITL 2 FACTOR XIA. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 30 26949 2020 REMARK 1 REFN ESSN 1464-3405 REMARK 1 PMID 31932224 REMARK 1 DOI 10.1016/J.BMCL.2020.126949 REMARK 2 REMARK 2 RESOLUTION. 2.53 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.53 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 68.75 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 89.0 REMARK 3 NUMBER OF REFLECTIONS : 11860 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.177 REMARK 3 R VALUE (WORKING SET) : 0.176 REMARK 3 FREE R VALUE : 0.236 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 2.500 REMARK 3 FREE R VALUE TEST SET COUNT : 297 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.53 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.77 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 78.78 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2461 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.1738 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2409 REMARK 3 BIN R VALUE (WORKING SET) : 0.1725 REMARK 3 BIN FREE R VALUE : 0.2313 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 2.11 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 52 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1897 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 84 REMARK 3 SOLVENT ATOMS : 103 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 39.87 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 22.99 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -4.60530 REMARK 3 B22 (A**2) : -4.60530 REMARK 3 B33 (A**2) : 9.21070 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.330 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.391 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.263 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.361 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.259 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.924 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.876 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2055 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 2802 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 686 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 40 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 335 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2055 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 260 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2363 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.13 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.58 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 17.48 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5QTU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 18-OCT-19. REMARK 100 THE DEPOSITION ID IS D_1001402399. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 08-SEP-11 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU FR-E SUPERBRIGHT REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.54178 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MICROMAX CONFOCAL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : RIGAKU SATURN 92 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 11923 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.530 REMARK 200 RESOLUTION RANGE LOW (A) : 105.660 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 89.7 REMARK 200 DATA REDUNDANCY : 10.40 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.10400 REMARK 200 FOR THE DATA SET : 23.5000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.53 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.67 REMARK 200 COMPLETENESS FOR SHELL (%) : 80.9 REMARK 200 DATA REDUNDANCY IN SHELL : 10.50 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.36800 REMARK 200 FOR SHELL : 7.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: 4TY7 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 61.92 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.23 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM SODIUM ACETATE, PH 4.6, 25% REMARK 280 (W/V) MEPEG2000, 200 MM AMMONIUM SULFATE, THEN TRANSFERRED TO REMARK 280 100 MM TRIS-HCL, PH 7.0, 25% (W/V) MEPEG2000, 200 MM AMMONIUM REMARK 280 SULFATE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 32 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+1/3 REMARK 290 6555 -X,-X+Y,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 70.44000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 35.22000 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 35.22000 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 70.44000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 810 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 11380 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -7.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, H REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 S SO4 A 302 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 HIS A 246 REMARK 465 HIS A 247 REMARK 465 HIS A 248 REMARK 465 HIS A 249 REMARK 465 HIS A 250 REMARK 465 HIS A 251 REMARK 465 MET H 352 REMARK 465 ASP H 353 REMARK 465 ASP H 354 REMARK 465 ASP H 355 REMARK 465 ASP H 356 REMARK 465 LYS H 357 REMARK 465 MET H 358 REMARK 465 ASP H 359 REMARK 465 ASN H 360 REMARK 465 GLU H 361 REMARK 465 ARG H 369 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 61 CG CD OE1 OE2 REMARK 470 GLU A 78 CG CD OE1 OE2 REMARK 470 LYS A 126 CG CD CE NZ REMARK 470 ARG A 129 CG CD NE CZ NH1 NH2 REMARK 470 ASN A 130 CG OD1 ND2 REMARK 470 ARG A 148 CG CD NE CZ NH1 NH2 REMARK 470 GLU A 185 CG CD OE1 OE2 REMARK 470 LYS H 365 CD CE NZ REMARK 470 LYS H 367 CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TRP A 27 69.10 -119.14 REMARK 500 LEU A 41 -60.06 -109.05 REMARK 500 GLN A 50 20.03 -141.59 REMARK 500 TYR A 133 111.49 76.57 REMARK 500 ASP A 149 -144.13 -163.60 REMARK 500 ASP A 189 -178.94 -171.56 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue QEV A 301 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue SO4 A 302 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 303 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 304 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 305 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 306 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 307 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 308 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 309 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 310 REMARK 800 REMARK 800 SITE_IDENTIFIER: AD2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue EDO A 311 DBREF 5QTU A 16 245 UNP P03951 FA11_HUMAN 388 625 DBREF 5QTU H 357 369 UNP P03951 FA11_HUMAN 375 387 SEQADV 5QTU GLY A 113 UNP P03951 ASN 491 CONFLICT SEQADV 5QTU GLY A 115 UNP P03951 THR 493 CONFLICT SEQADV 5QTU HIS A 246 UNP P03951 EXPRESSION TAG SEQADV 5QTU HIS A 247 UNP P03951 EXPRESSION TAG SEQADV 5QTU HIS A 248 UNP P03951 EXPRESSION TAG SEQADV 5QTU HIS A 249 UNP P03951 EXPRESSION TAG SEQADV 5QTU HIS A 250 UNP P03951 EXPRESSION TAG SEQADV 5QTU HIS A 251 UNP P03951 EXPRESSION TAG SEQADV 5QTU MET H 352 UNP P03951 INITIATING METHIONINE SEQADV 5QTU ASP H 353 UNP P03951 EXPRESSION TAG SEQADV 5QTU ASP H 354 UNP P03951 EXPRESSION TAG SEQADV 5QTU ASP H 355 UNP P03951 EXPRESSION TAG SEQADV 5QTU ASP H 356 UNP P03951 EXPRESSION TAG SEQRES 1 A 244 ILE VAL GLY GLY THR ALA SER VAL ARG GLY GLU TRP PRO SEQRES 2 A 244 TRP GLN VAL THR LEU HIS THR THR SER PRO THR GLN ARG SEQRES 3 A 244 HIS LEU CYS GLY GLY SER ILE ILE GLY ASN GLN TRP ILE SEQRES 4 A 244 LEU THR ALA ALA HIS CYS PHE TYR GLY VAL GLU SER PRO SEQRES 5 A 244 LYS ILE LEU ARG VAL TYR SER GLY ILE LEU ASN GLN SER SEQRES 6 A 244 GLU ILE LYS GLU ASP THR SER PHE PHE GLY VAL GLN GLU SEQRES 7 A 244 ILE ILE ILE HIS ASP GLN TYR LYS MET ALA GLU SER GLY SEQRES 8 A 244 TYR ASP ILE ALA LEU LEU LYS LEU GLU THR THR VAL GLY SEQRES 9 A 244 TYR GLY ASP SER GLN ARG PRO ILE CYS LEU PRO SER LYS SEQRES 10 A 244 GLY ASP ARG ASN VAL ILE TYR THR ASP CYS TRP VAL THR SEQRES 11 A 244 GLY TRP GLY TYR ARG LYS LEU ARG ASP LYS ILE GLN ASN SEQRES 12 A 244 THR LEU GLN LYS ALA LYS ILE PRO LEU VAL THR ASN GLU SEQRES 13 A 244 GLU CYS GLN LYS ARG TYR ARG GLY HIS LYS ILE THR HIS SEQRES 14 A 244 LYS MET ILE CYS ALA GLY TYR ARG GLU GLY GLY LYS ASP SEQRES 15 A 244 ALA CYS LYS GLY ASP SER GLY GLY PRO LEU SER CYS LYS SEQRES 16 A 244 HIS ASN GLU VAL TRP HIS LEU VAL GLY ILE THR SER TRP SEQRES 17 A 244 GLY GLU GLY CYS ALA GLN ARG GLU ARG PRO GLY VAL TYR SEQRES 18 A 244 THR ASN VAL VAL GLU TYR VAL ASP TRP ILE LEU GLU LYS SEQRES 19 A 244 THR GLN ALA VAL HIS HIS HIS HIS HIS HIS SEQRES 1 H 18 MET ASP ASP ASP ASP LYS MET ASP ASN GLU CYS THR THR SEQRES 2 H 18 LYS ILE LYS PRO ARG HET QEV A 301 73 HET SO4 A 302 5 HET EDO A 303 4 HET EDO A 304 4 HET EDO A 305 4 HET EDO A 306 4 HET EDO A 307 4 HET EDO A 308 4 HET EDO A 309 4 HET EDO A 310 4 HET EDO A 311 4 HETNAM QEV METHYL [(3R,7S)-7-{[1-(3-CHLORO-2-FLUOROPHENYL)-5- HETNAM 2 QEV METHYL-1H-IMIDAZOLE-4-CARBONYL]AMINO}-3-METHYL-2-OXO- HETNAM 3 QEV 2,3,4,5,6,7-HEXAHYDRO-1H-12,8-(METHENO)-1,9- HETNAM 4 QEV BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE HETNAM SO4 SULFATE ION HETNAM EDO 1,2-ETHANEDIOL HETSYN EDO ETHYLENE GLYCOL FORMUL 3 QEV C31 H30 CL F N6 O4 FORMUL 4 SO4 O4 S 2- FORMUL 5 EDO 9(C2 H6 O2) FORMUL 14 HOH *103(H2 O) HELIX 1 AA1 ALA A 55 TYR A 58B 5 6 HELIX 2 AA2 SER A 62 LYS A 64 5 3 HELIX 3 AA3 ASN A 72 ILE A 76 5 5 HELIX 4 AA4 MET A 96 GLY A 100 5 5 HELIX 5 AA5 SER A 125 ASN A 130 5 6 HELIX 6 AA6 THR A 164 TYR A 171 1 9 HELIX 7 AA7 TYR A 234 GLN A 243 1 10 SHEET 1 AA1 8 THR A 20 ALA A 21 0 SHEET 2 AA1 8 GLN A 156 LYS A 159 -1 O LYS A 157 N THR A 20 SHEET 3 AA1 8 CYS A 136 GLY A 140 -1 N GLY A 140 O GLN A 156 SHEET 4 AA1 8 PRO A 198 HIS A 203 -1 O SER A 200 N TRP A 137 SHEET 5 AA1 8 VAL A 206 TRP A 215 -1 O HIS A 208 N CYS A 201 SHEET 6 AA1 8 GLY A 226 ASN A 230 -1 O VAL A 227 N TRP A 215 SHEET 7 AA1 8 MET A 180 ALA A 183 -1 N ALA A 183 O GLY A 226 SHEET 8 AA1 8 LEU A 162 VAL A 163 -1 N VAL A 163 O CYS A 182 SHEET 1 AA2 7 GLN A 30 THR A 35 0 SHEET 2 AA2 7 ARG A 39 GLY A 48 -1 O LEU A 41 N LEU A 33 SHEET 3 AA2 7 TRP A 51 THR A 54 -1 O LEU A 53 N SER A 45 SHEET 4 AA2 7 ALA A 104 LEU A 108 -1 O ALA A 104 N THR A 54 SHEET 5 AA2 7 PHE A 83 ILE A 90 -1 N ILE A 89 O LEU A 105 SHEET 6 AA2 7 LEU A 65A TYR A 67 -1 N VAL A 66 O PHE A 83 SHEET 7 AA2 7 GLN A 30 THR A 35 -1 N HIS A 34 O ARG A 65B SSBOND 1 CYS A 42 CYS A 58 1555 1555 2.03 SSBOND 2 CYS A 122 CYS H 362 1555 1555 2.04 SSBOND 3 CYS A 136 CYS A 201 1555 1555 2.05 SSBOND 4 CYS A 168 CYS A 182 1555 1555 2.03 SSBOND 5 CYS A 191 CYS A 219 1555 1555 2.03 CISPEP 1 SER A 36A PRO A 36B 0 -1.36 SITE 1 AC1 21 ARG A 39 HIS A 40 LEU A 41 TYR A 143 SITE 2 AC1 21 ILE A 151 ASP A 189 ALA A 190 CYS A 191 SITE 3 AC1 21 LYS A 192 GLY A 193 SER A 195 THR A 213 SITE 4 AC1 21 SER A 214 TRP A 215 GLY A 218 GLY A 226 SITE 5 AC1 21 VAL A 227 TYR A 228 EDO A 309 EDO A 310 SITE 6 AC1 21 HOH A 413 SITE 1 AC2 2 ARG A 170 ARG A 184B SITE 1 AC3 4 ASN A 49 THR A 111 VAL A 112 TYR A 114 SITE 1 AC4 2 ARG A 24 SER A 99 SITE 1 AC5 9 ARG A 24 GLY A 25 GLU A 26 TRP A 27 SITE 2 AC5 9 PRO A 28 ILE A 70 LEU A 71 LEU A 155 SITE 3 AC5 9 HOH A 437 SITE 1 AC6 4 SER A 81 LYS A 192 GLU A 217 GLY A 218 SITE 1 AC7 1 HIS A 178 SITE 1 AC8 5 SER A 99 GLY A 100 TYR A 101 THR A 177 SITE 2 AC8 5 LYS A 179 SITE 1 AC9 6 HIS A 57 ALA A 97 SER A 214 TRP A 215 SITE 2 AC9 6 QEV A 301 HOH A 413 SITE 1 AD1 3 GLY A 113 TYR A 114 QEV A 301 SITE 1 AD2 6 TYR A 94 MET A 96 ALA A 97 GLU A 98 SITE 2 AD2 6 SER A 117 HOH A 423 CRYST1 79.390 79.390 105.660 90.00 90.00 120.00 P 32 2 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012596 0.007272 0.000000 0.00000 SCALE2 0.000000 0.014545 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009464 0.00000